Clinical trials
Hepatitis B Infection clinical trials
Below are recruiting hepatitis b infection clinical trials, each written for real people, not researchers. We’re tracking 134 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05766449Recruiting
Study of liver inflammation and scarring in hepatitis B or fatty liver
This study looks at what factors predict liver inflammation, scarring (fibrosis), and health outcomes in people with long-term hepatitis B or fatty liver disease. The goal is to better understand who is more likely to worsen over time.
NanjingAges 18 years+ - NCT05255978Recruiting
Follow-up study for hepatitis B with fatty liver
This observational study looks at people with chronic hepatitis B who also have fatty liver (non-alcoholic fatty liver disease). It follows how their liver health changes over time and may help doctors understand outcomes and risk factors.
Wuhan, HubeiAges 18 years+ - NCT05403047RecruitingPhase 4
Preventing mom-to-baby hepatitis B with tenofovir
This study tests whether the medicine tenofovir disoproxil can help prevent passing hepatitis B from mother to baby during pregnancy. It is for pregnant women with an active hepatitis B infection who are early in their pregnancy (less than 24 weeks).
TokonbéréAges 16 years+ - NCT05583006Recruiting
Switch from entecavir to tenofovir for chronic hepatitis B
This trial studies switching people with chronic hepatitis B from entecavir (ETV) to tenofovir alafenamide (TAF). It may help if you feel your current entecavir treatment isn’t working well enough or is inconvenient.
Taichung, TaiwanAges 20 years+ - NCT04357600Enrolling by invitationPhase 1/Phase 2
Stem cell treatment for hepatitis B–related cirrhosis
This early-stage trial tests umbilical cord “mesenchymal” stem cells in people with liver scarring (cirrhosis) that is caused by hepatitis B. It may help improve liver function and related complications, but it is mainly designed to check safety and how well the treatment works.
Jakarta, DKI JakartaAges 18–65 - NCT06923280Recruiting
Sequential Pegylated Interferon After RNA-Targeted Hepatitis B Therapy
This trial tests a sequence of pegylated interferon (PEG-IFN) shots for people with chronic hepatitis B who have already had a significant drop in their virus levels after taking a newer type of RNA-targeting medicine. The goal is to see if this approach can help clear the virus even further.
Beijing, ChinaAges 18–80 - NCT03792919RecruitingPhase 4
Stopping long-term hepatitis B medicine vs continuing
This study compares outcomes for people with chronic hepatitis B who have long-term, stable viral suppression: stopping their antiviral medicine versus continuing it. It may help answer whether it’s safe to stop treatment in the right patients.
Hong Kong, Hong Kong SARAges Any age - NCT03920618Recruiting
Testing three HBV medicines for severe liver flare (ACLF)
This study compares three hepatitis B (HBV) medicines to see which treatment helps people with a severe liver flare. You may be eligible if you have confirmed HBV and lab results showing significant liver stress.
Guangzhou, GuangdongAges 12–65 - NCT04231565Recruiting
Testing antiviral medicines for hepatitis B with normal liver blood tests
This trial studies how well nucleoside (nucleoside-acid) type antiviral medicines control hepatitis B in people whose liver enzyme test (ALT) is currently normal. It may help those with active hepatitis B but no major liver inflammation on recent bloodwork.
Guangzhou, GuangdongAges 18–65 - NCT04597164Recruiting
Test a hepatitis B–targeted treatment for serious liver failure
This trial studies a combination approach called DPMAS and low-volume plasma exchange for people with hepatitis B–related acute-on-chronic liver failure. If you qualify, the goal is to improve your liver function and reduce serious complications from liver failure.
Guangzhou, GuangdongAges 18–65 - NCT05304234RecruitingPhase 2
Testing ways to detect liver cancer risk in Native patients
This Phase 2 study focuses on people at higher risk for liver cancer due to liver scarring or chronic hepatitis B. It may help improve screening and outcomes for American Indian and Alaska Native people who could benefit from closer monitoring.
Tahlequah, OklahomaAges 18–75 - NCT05686759RecruitingPhase 3
Tested IV Hepabig in liver-transplant patients with hepatitis B
This Phase 3 study checks whether an undiluted IV infusion of I.V.-Hepabig inj is safe and works to help prevent hepatitis B from coming back after a liver transplant. It is mainly for adults who had a hepatitis B–related liver transplant and already received Hepabig regularly.
Goyang-si, Gyeonggi-doAges 18–64 - NCT06323681Recruiting
Lower-dose interferon for chronic hepatitis B patients who've tried it before
This study tests a lower dose of pegylated interferon for people with chronic hepatitis B whose virus levels dropped significantly during a previous interferon treatment. It aims to see if a second round can further reduce or clear the virus.
Shanghai, Shanghai MunicipalityAges 18–65 - NCT06364930RecruitingPhase 4
SGLT2 inhibitor to prevent liver problems in hepatitis B and diabetes
This study tests if adding a diabetes medicine called an SGLT2 inhibitor to your current treatment can help prevent liver complications in people with chronic hepatitis B and type 2 diabetes or prediabetes. If you have early liver scarring and stable diabetes treatment, this could offer extra protection for your liver.
Hong KongAges 18 years+ - NCT06457477Recruiting
PD-1 antibody and peginterferon for chronic hepatitis B
This trial tests a combination of a PD-1 antibody (a type of immunotherapy) and peginterferon alpha for people with chronic hepatitis B whose virus is already under control but whose surface antigen levels haven't improved much with standard therapy. It aims to see if the combo can help reduce the hepatitis B surface antigen further.
Beijing, Beijing MunicipalityAges 18–65 - NCT06550622Recruiting
Better Detection of Hepatitis B Virus After Treatment
This study looks at a new way to detect the hepatitis B virus in the blood, even after standard tests say it's gone. It may help people who have stopped treatment and want to see if the virus comes back.
Shanghai, Shanghai MunicipalityAges 18–65 - NCT06623071Recruiting
HBV viral load test validation study
This study is testing a new blood test that measures the amount of hepatitis B virus (HBV) in your body. It helps see if the test works as well as current approved tests.
Frépillon, Ile de FranaceAges 18 years+ - NCT06947356Recruiting
TAF vs TDF to prevent passing hepatitis B to babies
This trial tests if TAF is safer and as effective as TDF for pregnant women with high hepatitis B viral loads to prevent passing the virus to their babies. You may qualify if you are pregnant, between 20-28 weeks, and have high viral levels.
Guangzhou, GuangdongAges 20–40 - NCT06966232RecruitingPhase 3
Using entecavir to prevent hepatitis B flare-up in gastrointestinal cancer patients
This trial tests whether giving the antiviral drug entecavir before or at the first sign of hepatitis B reactivation can prevent liver problems in gastrointestinal cancer patients who are inactive hepatitis B carriers and are starting chemotherapy or immunotherapy.
Guangzhou, GuangdongAges 18–75 - NCT07189377RecruitingPhase 4
Light, ex-vivo treatment and antivirals for lungs from hepatitis B donors
This trial tests a new way to safely use donor lungs that carry the hepatitis B virus (HBV). It combines a special light treatment, ex-vivo lung perfusion (cleaning the lungs outside the body), and antiviral medicines to prevent infection in the recipient. If you are on the lung transplant list and have been vaccinated against hepatitis B, this study may help expand your donor options.
Toronto, OntarioAges 18 years+ - NCT07275918RecruitingPhase 1
Study of SA1211 injection for chronic hepatitis B
This study tests a new injection called SA1211 for people with chronic hepatitis B. It will help see if the treatment is safe and how it works in the body.
Changchun, JilinAges 18–65 - NCT07449091Recruiting
HBV undetectable equals untransmissible study
This study checks if having undetectable hepatitis B virus (HBV) means you cannot pass it to others. It tests this idea in people with chronic HBV who are on treatment, those not on treatment, and healthy controls.
New York, New YorkAges 18–65 - NCT07589985Recruiting
Hepatitis B and Liver Health Study in Zambia
This research study follows people with hepatitis B (a liver infection) in Zambia to understand how their bodies respond to treatment and what happens to the virus over time. It includes people with hepatitis B alone, those also living with HIV, and those whose hepatitis B has cleared.
LusakaAges 18 years+ - NCT06777173Enrolling by invitation
Antiviral and Immunotherapy for Chronic Hepatitis B
This study tests a new combination of antiviral medicine and an immune-boosting therapy for adults with chronic hepatitis B. It is designed for people who are in the active phase of the infection and have not been treated before.
BeijingAges 18–65
Hear when a new Hepatitis B Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for hepatitis b infection?
- Yes. Clin2 currently lists 134 recruiting hepatitis b infection studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hepatitis b infection trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hepatitis b infection trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.